BR112014001979A2 - uso do anticorpo i-3859 para a detecção e diagnóstico de câncer - Google Patents

uso do anticorpo i-3859 para a detecção e diagnóstico de câncer

Info

Publication number
BR112014001979A2
BR112014001979A2 BR112014001979A BR112014001979A BR112014001979A2 BR 112014001979 A2 BR112014001979 A2 BR 112014001979A2 BR 112014001979 A BR112014001979 A BR 112014001979A BR 112014001979 A BR112014001979 A BR 112014001979A BR 112014001979 A2 BR112014001979 A2 BR 112014001979A2
Authority
BR
Brazil
Prior art keywords
diagnosis
antibody
cancer detection
cancer
cxcr4
Prior art date
Application number
BR112014001979A
Other languages
English (en)
Portuguese (pt)
Inventor
Jouhanneaud Alexandra
Klinguerhamour Christine
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112014001979A2 publication Critical patent/BR112014001979A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112014001979A 2011-07-29 2012-07-30 uso do anticorpo i-3859 para a detecção e diagnóstico de câncer BR112014001979A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513345P 2011-07-29 2011-07-29
EP11306000 2011-07-29
PCT/EP2012/064876 WO2013017562A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Publications (1)

Publication Number Publication Date
BR112014001979A2 true BR112014001979A2 (pt) 2017-02-21

Family

ID=47628653

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001979A BR112014001979A2 (pt) 2011-07-29 2012-07-30 uso do anticorpo i-3859 para a detecção e diagnóstico de câncer

Country Status (14)

Country Link
US (1) US20140170677A1 (https=)
EP (1) EP2736926A1 (https=)
JP (1) JP6138780B2 (https=)
KR (1) KR20140047127A (https=)
CN (1) CN103717620A (https=)
AR (1) AR087363A1 (https=)
AU (2) AU2012292116A1 (https=)
BR (1) BR112014001979A2 (https=)
CA (1) CA2842552A1 (https=)
IL (1) IL230693A0 (https=)
MX (1) MX2014001160A (https=)
RU (1) RU2636032C2 (https=)
WO (1) WO2013017562A1 (https=)
ZA (1) ZA201400500B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6232689B2 (ja) 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
EP3365682B1 (en) * 2015-10-23 2020-10-07 Novartis AG System for deriving cell-to-cell spatial proximities
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US20210349099A1 (en) * 2017-11-07 2021-11-11 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
JP2021521439A (ja) * 2018-04-13 2021-08-26 エックス４ ファーマシューティカルズ， インコーポレイテッド がん血清バイオマーカーおよびその使用方法
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068357B2 (en) 1998-03-30 2014-12-10 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2004096839A1 (en) * 2003-05-02 2004-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
KR101722261B1 (ko) * 2006-10-02 2017-04-03 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
JP6138780B2 (ja) 2017-05-31
AU2012292116A1 (en) 2014-02-06
IL230693A0 (en) 2014-03-31
MX2014001160A (es) 2014-07-14
JP2014523920A (ja) 2014-09-18
CA2842552A1 (en) 2013-02-07
EP2736926A1 (en) 2014-06-04
KR20140047127A (ko) 2014-04-21
ZA201400500B (en) 2014-11-26
AR087363A1 (es) 2014-03-19
AU2017204043A1 (en) 2017-07-06
WO2013017562A1 (en) 2013-02-07
CN103717620A (zh) 2014-04-09
RU2636032C2 (ru) 2017-11-17
RU2014103054A (ru) 2015-09-10
US20140170677A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
BR112014001979A2 (pt) uso do anticorpo i-3859 para a detecção e diagnóstico de câncer
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
UA113712C2 (xx) Антитіло до fap і способи його застосування
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
BR112015007184A2 (pt) combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
BR112015024553A2 (pt) anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
MX362720B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
BRPI1006134A2 (pt) anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
BR112012028764A2 (pt) anticor-pos antifgfr2
BR112013008255A2 (pt) anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
MX2014015088A (es) Anticuerpos anti-tofacitinib y usos de los mismos para monitorear farmacos.
WO2012154983A3 (en) Systems and methods for anti-pax8 antibodies
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
BR112015021586A2 (pt) formulações de morfina
WO2015051320A3 (en) Anti-sox10 antibody systems and methods
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2014100220A3 (en) Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2525 DE 28-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.